<h4>Purpose</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for managing both obesity and diabetes mellitus, two major risk factors for adverse outcomes following total knee arthroplasty (TKA). Here, GLP1R is linked to diabetes mellitus.